z-logo
open-access-imgOpen Access
Formulation of Extended-Release Ranolazine Tablet and Investigation Its Stability in the Accelerated Stability Condition At 40⁰C And 75 % Humidity
Author(s) -
Farzad Khajavi
Publication year - 2021
Language(s) - English
DOI - 10.47363/jprsr/2021(2)106
Subject(s) - ranolazine , dissolution , chromatography , materials science , humidity , dosage form , chemistry , diffusion , thermodynamics , pharmacology , physics , medicine , organic chemistry
Formulation of Ranolazine in the form of extended-release tablet in 500 mg dosage form was performed using Eudragit L100-55 as a retarding agent. Drugrelease profiles were investigated in comparison with the reference Ranexa extended-release 500 mg tablet. F2 and f1 were calculated as 64.16 and 8.53, respectively. According to Peppas equation, the release of drug is controlled by diffusion (n=0.5). The tablets were put into accelerated stability condition (40⁰C, 75% humidity) for 3 and 6 months. The dissolution release profiles and other physical and chemical characteristics of the tablets confirmed the robustness and stability of formulation in this condition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here